Sodium thiosulfate attenuates angiotensin II-induced hypertension, proteinuria and renal damage

AS Frenay*
PM Snijder*
AM Koning
M Bachtler
AJ Kwakernaak
E van den Berg
EM Bos
JL Hillebrands
G Navis
HGD Leuvenink
H van Goor

*These authors contributed equally to the manuscript

Published in Nitric Oxide
Abstract

Hypertension and proteinuria are important mediators of renal damage. Despite therapeutic interventions, the number of patients with end stage renal disease steadily increases. Hydrogen sulfide (H\textsubscript{2}S) is an endogenously produced gasotransmitter with vasodilatory, anti-inflammatory and antioxidant properties. These beneficial characteristics make H\textsubscript{2}S an attractive candidate for pharmacological use in hypertensive renal disease. We investigated the protective properties of H\textsubscript{2}S in Angiotensin II (Ang II)-induced hypertensive renal disease in rats. Treatment with the H\textsubscript{2}S donors NaHS and sodium thiosulfate (STS) during three weeks of Ang II infusion reduced hypertension, proteinuria, oxidative stress and renal functional and structural deterioration. In an ex vivo isolated perfused kidney setup NaHS, but not STS, reduced intrarenal pressure. The effect of NaHS could partially be explained by its activation of the ATP-sensitive potassium channels. In conclusion, treatment with H\textsubscript{2}S attenuates Ang II-associated functional and structural renal deterioration, suggesting that intervention in H\textsubscript{2}S production pathways has potential therapeutic benefit and might be a valuable addition to the already existing antihypertensive and renoprotective therapies.
Introduction

Chronic kidney disease (CKD) is a highly prevalent disorder associated with extensive morbidity and mortality worldwide. Hypertension and proteinuria are major contributors to the progression of CKD. Both are important actors in enhancing structural and functional renal deterioration through changes in intrarenal hemodynamics and inflammation, thereby promoting the release of chemokines and reactive oxygen species (ROS). This results in stimulation of extracellular matrix synthesis and enhancement of cellular apoptosis. Increased activity of the renin-angiotensin-aldosterone system (RAAS) resulting in augmented Angiotensin II (Ang II) signaling is often the underlying cause of hypertension and proteinuria. Functional RAAS modulation has afforded great progress in renoprotection by reducing blood pressure, proteinuria and the rate of renal function loss. Although RAAS blockade stands out as the most effective renoprotective treatment, in many cases renal disease ultimately progresses to end-stage renal failure with the deplorable need for dialysis or transplantation. This prompts for additional modes of intervention by either optimization of RAAS blockade based therapies or targeting other pathophysiological pathways involved in the development of CKD.

Hydrogen Sulfide (H$_2$S) is acknowledged as the third gasotransmitter in addition to nitric oxide (NO) and carbon monoxide (CO), and modulates many physiological functions. It is endogenously produced from the amino acid L-cysteine by cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS) and from D-cysteine by 3-mercaptopyruvate sulfurtransferase (3-MST). In the vasculature H$_2$S functions as an endothelial cell-derived relaxing factor via direct activation of ATP-sensitive potassium (K$_{ATP}$) channels. Accordingly, CSE-deficient mice and CBS heterozygous mice develop hypertension. CSE can act as an endogenous modulator of oxidative stress, as CSE-deficient mice have increased renal damage after ischemia-reperfusion. Exogenous treatment with the soluble sulfide salt NaHS attenuated the hypertensive effects of NO synthase (NOS) inhibition and has preventive and therapeutic effects on renovascular hypertension by inhibiting plasma renin activity. In addition, H$_2$S stimulates cellular proliferation and angiogenesis and reduces inflammation. Endogenous H$_2$S functions as a signaling molecule by regulating protein activity through S-sulfhydration which is a form of posttranslational modification. Furthermore, H$_2$S can play a detoxifying role during oxidative stress by direct scavenging of ROS or increasing the formation of the antioxidant glutathione. Progression of renal disease in a CKD model is associated with depletion of H$_2$S and its producing enzymes. Recently, urinary sulfur metabolites were found to associate with a favorable cardiovascular risk profile and even improved survival in renal transplant recipients. Given the cytoprotective features of H$_2$S, its deficiency may contribute to progression of CKD and its systemic complications.


H₂S can be delivered in vivo via gaseous administration or through the use of soluble sulfide salts like NaHS and Na₂S. In addition, several slow-release H₂S donors have been developed. Another possibility is the use of thiosulfate (TS), an endogenous actor in the enzymatic pathways of H₂S modulation in mammalian cells. Increasing evidence grounds the idea that a dynamic conversion exists between the two substances. In humans, the short term therapeutic use of sodium TS (STS) has been proven safe for the treatment of calciphylaxis.

The vasodilating and cytoprotective features of H₂S make it an attractive therapeutic candidate for reducing the damaging effects of hypertension and proteinuria. In the experimental setting, Ang II infusion causes hypertension, proteinuria and renal damage. We used this model to investigate the renoprotective properties of sulfide containing compounds.

**Materials and methods**

**Animals**

Male Sprague Dawley rats (240-280 gram, Harlan, Zeist, the Netherlands) were housed under standard conditions with a 12 hour light-dark cycle at the animal research facility with ad libitum access to food and water. Experimental procedures were in agreement with institutional and legislator regulations and approved by the local ethics committee for animal experiments.

**Ang II infusion and NaHS or STS treatment**

Osmotic minipumps (model 2004, Alzet, Cupertino, CA, USA) were placed subcutaneously under general anesthesia (2% Isoflurane/O₂) for continuous administration of Ang II (435 ng/kg/min, n = 7/group; Bachem, Weil am Rhein, Germany) or vehicle (0.9% NaCl, n = 6). Post-operatively, all rats received a subcutaneous injection of 50 μg/kg buprenorphin (Schering-Plough, Houten, the Netherlands) for analgesic purposes and were allowed to recover from surgery at 37°C in a ventilated incubator. At placement of the pumps Ang II-infused rats were randomized to either 0.9% NaCl, NaHS (5.6 mg/kg/day; Sigma, Zwijndrecht, the Netherlands) or STS (1 g/kg/day; Sigma, Zwijndrecht, the Netherlands) treatment. 0.9% NaCl-infused rats received treatment with 0.9% NaCl.

During the three weeks of infusion rats received intraperitoneal (ip) injections with one of the compounds twice a day. At baseline, blood was collected via orbital puncture. On a weekly basis, body weight was measured and rats were placed in metabolic cages for collection of 24-hour urine. Chlorhexidin was added to the urine as an antiseptic.
agent to prevent bacterial growth. After three weeks blood pressure was measured under general anesthesia (2% Isoflurane/O₂) via an intra-aortic probe (Cardiocap/5, GE Healthcare, Little Chalfont, Buckinghamshire, UK). Subsequently, rats were sacrificed and blood was collected in heparin and EDTA containing tubes and centrifuged for 10 minutes at 1000 rcf. Plasma was collected and stored at -80° C. Kidneys were perfused with 0.9% NaCl. Coronal slices were fixed in 4% paraformaldehyde and paraffin embedded for immunohistochemical analysis or immediately snap frozen in liquid nitrogen and stored at -80° C for molecular analysis.

Plasma and urine biochemical analysis

Plasma and urine levels of creatinine, urea and electrolytes were determined by standard assays from Roche on the Roche Modular (Roche Diagnostics GmbH, Mannheim, Germany) according to routine procedures in our clinical chemical laboratory. Urinary protein levels were determined with the pyrogallol red molybdate method. Urinary TS was determined by a specific HPLC method as described previously. In short, 25 μL of urine was derivatized with 5 μL of 46 mM monobromobimane, 25 μL of acetonitrile, and 25 μL of 160 mM HEPES/16 mM EDTA pH 8 buffer (Invitrogen, Carlsbad, CA, USA) for 30 minutes in the dark. Derivatization of thiol groups was stopped by 50 μL of 65 mM methanosulfonic acid (Fluka, Buchs, Switzerland) and proteins were removed by recentrifugation.

Qualitative Real-time Polymerase Chain Reaction

Rat renal tissue containing cortex and medulla was homogenized in lysis buffer and total RNA was extracted using the TRIZOL method (Invitrogen, Carlsbad, USA). RNA concentrations were measured by a nanodrop UV-detector (Nanodrop Technologies, Wilminton, DE). cDNA was synthesized using Superscript II with random hexamer primers (Invitrogen, Carlsbad, USA). Gene expression (Applied Biosystems, Foster City, CA, USA) was determined by qualitative realtime-PCR (qRT-PCR) based on the Taqman methodology. HPRT was used as a housekeeping gene with the following primers (Integrated DNA Technologies) and probe (Eurogentec): Forward: 5’-GCC CTT GAC TAT AAT GAG CAC TTC A-3’; Reverse: 5’-TCT TTT AGG CTT TGT ACT TGG CTT TT-3’ and Probe: 6-FAM 5’-ATT TGA ATC ATG TTT GTG TCA TCA GCG AAA GTG-3’ TAMRA. The other primers were obtained from Applied Biosystems as Assays-on-Demand (AOD) gene expression products. The AOD ID’s used were: Coll3a1 (Collagen 3) Rn01437683_m1, Acta2 (αSMA) Rn01759928_g1, Hac1r1 (KIM-1) Rn00597703_m1, CTH (CSE) Rn00567128_m1, CBS Rn00560948_m1, Mpst (3-MST) Rn00593744_m1, Renin Rn00561847_m1, TGF-β1 Rn00572010_m1 and Cybb (NOX2) Rn00576710_m1. The qRT-PCR reaction mixture
contained 20 ng cDNA template and 5µl PCR-mastermix. Nuclease free water was added to a total volume of 10 µl. All assays were performed in triplicate. The thermal profile was 15 minutes at 95° C, followed by 40 cycles of 15 seconds at 95° C and 1 minute at 60° C. The average Ct values for target genes were subtracted from the average housekeeping gene Ct values to yield the delta Ct. Results were expressed as $2^{-\Delta Ct}$.

**Immunohistochemistry**

For immunostaining, deparaffinized sections were subjected to heat-induced antigen retrieval by overnight incubation with 0.1 M Tris/HCl buffer (pH 9.0) at 80° C (ED1, αSMA, KIM-1, desmin) or by incubation with EDTA buffer (pH 8.0) heated by a microwave (Collagen 3). Endogenous peroxidase was blocked with 0.075% H$_2$O$_2$ in phosphate buffered saline (PBS, pH 7.4) for 30 minutes. Primary antibodies for macrophages (mouse anti-CD68 ED1, MCA341R AbD, 1:750, Serotec Ltd, Oxford, UK), αSMA (mouse anti-SMA, clone 1A4 A2547, 1:10.000, Sigma, Zwijndrecht, the Netherlands), Collagen 3 (goat anti-type 3 Collagen, 1330-01, 1:75, Southern Biotech, Birmingham, Alabama, USA), Desmin (mouse anti-desmin NCL-DES-DER11, 1:500, Novocastra, Rijswijk, the Netherlands) or KIM-1 (rabbit anti-KIM-1 peptide 9, 1:400, gift V. Baily) were incubated for 60 minutes at room temperature. Binding was detected using sequential incubation with peroxidase-labeled secondary and tertiary antibodies (Dakopatts, Glostrup, Denmark) for 30 minutes. All antibodies were diluted with PBS supplemented with 1% BSA. At the secondary and tertiary antibody dilutions 1% normal rat serum was added. Peroxidase activity was developed using 3,3’-diaminobenzidine tetrachloride for 10 minutes containing 0.03% H$_2$O$_2$. Counterstaining was performed using Mayer’s hematoxylin. Appropriate isotype and PBS controls were consistently negative.

**Analysis of histopathological changes**

Kidney sections were scanned using an Aperio Scanscope GS (Aperio Technologies, Vista, CA, USA). The extent of fibrotic changes (α-SMA, Collagen 3), glomerular damage (desmin) and proximal tubular ischemic damage (KIM-1) were determined using the Aperio positive pixel analysis v9.1 algorithm. For α-SMA, Collagen 3 and KIM-1 the ratio between the relative cortical staining intensity and the total cortical surface area was used. For desmin the ratio between glomerular staining intensity and total cortical glomerular area was calculated. Interstitial macrophages were counted manually by random selection of thirty renal cortical high powered fields. Histopathological analysis was performed in a blinded fashion.
Urinary Malondialdehyde measurements

Malondialdehyde (MDA), a major breakdown product of lipid peroxides, is generated after oxidative stress. MDA is a thiobarbituric acid-reactive substance and can be fluorescently measured after binding to thiobarbituric acid. Twenty µL urine was incubated with 90 µL of 3% SDS and 10 µL of 0.5 M butylated hydroxytoluene followed by addition of 400 µL 0.1 N HCl, 50 µL 10% phosphotungstic acid and 200 µL 0.7% 2-Thiobarbituric acid. The reaction mixture was incubated for 30 minutes at 95° C. After adding 800 µL of 1-butanol, the samples were centrifuged at 960 g for 10 minutes. Two hundred µL of the 1-butanol phase was fluorescently measured using 530 nm excitation and 590 nm emission wavelengths.

Isolated Perfused Kidney setup

To investigate the effect of NaHS and STS on intrarenal pressure we used an ex vivo isolated perfused kidney (IPK) setup. After induction of anaesthesia with 2% Isoflurane/O2, both kidneys and renal vessels from five healthy rats were isolated via a midline incision and subsequently a cannula was placed in the renal artery. Depending on the renal vascular anatomy either the right or left kidney was used. After placement in the IPK setup, the kidney was continuously perfused via the renal artery with warmed (37°C) and oxygenated (95% O2 and 5% CO2 gas mixture) Krebs-Ringer Bicarbonate (KRB) solution complemented with albumin and creatinine at a pH of 7.5 ± 0.05 and a PO2 ≈ 60 kPa, by using a roller pump (Ismatec mv-ca/04; Ismatec, Glattbrugg, Switzerland) delivering a constant flow of 8 mL/min throughout the experiment. The composition of the perfusion solution was as follows: 118.6 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 6.1 mM glucose, 7.1 mM creatinine and 50 g/L albumin. After connecting the kidney, the flow was gradually increased to 8 mL/min. Vascular responses were monitored by an electromechanical pressure transducer (Cobe; Arvada, CO) connected to a computer interface (LabView, National Instruments, Austin, TX). After an equilibration period, when renal vascular pressure had stabilized, 1-2 µM of phenylephrine (PE) (Sigma, Zwijndrecht, the Netherlands) was added to the perfusate to obtain a stable pre-contraction pressure of 200-250 mmHg. When the PE-induced vasoconstriction had reached a plateau, kidneys were subjected to subsequent doses of NaHS (1 µM, 10 µM, 100 µM, 1 mM and 5 mM (n=5)) or STS (1 µM (n=5), 10 µM, 100 µM (n=2), 1 mM, 5 mM (n=5)) for 1 minute. To investigate the role of KATP channels in NaHS-induced vasodilation, kidneys (n=5) were continuously perfused with 1 mM of Glibenclamide (Sigma, Zwijndrecht, the Netherlands) and subjected to subsequent doses of NaHS. After every dose we conducted a washout period of 4 minutes or continued when the intrarenal pressure had returned to baseline.
Statistical analysis

Data were analyzed and graphed using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). Statistical analyses were performed using t-tests, Mann-Whitney U tests, two-way ANOVA, one-way ANOVA or Kruskal-Wallis tests where appropriate. Bonferroni, Dunnett’s or Dunn’s postcorrection was applied where multiple comparisons were made. Normality was tested using the Kolmogorov-Smirnov test. Statistical significance was accepted at p<0.05. All data are expressed as the mean ± standard error of the mean (SEM) unless indicated otherwise.

Results

Rat characteristics – body weight and electrolytes

At baseline, there were no significant differences in body weight between the groups (Table 1). After 3 weeks, vehicle treated Ang II-infused rats had a significantly lower body weight compared to NaCl-infused controls (p<0.001). Treatment with NaHS partially prevented Ang II-induced weight loss (NaHS: p<0.05) (Table 1). Plasma sodium was significantly lower in vehicle treated rats compared to controls (p<0.001). No differences between groups were observed in plasma potassium and calcium levels (Table 1). In STS treated rats, urinary sodium excretion was significantly higher compared to vehicle treated rats (p<0.01). Urinary excretion of calcium was increased in Ang II-infused rats treated with vehicle compared to controls (p<0.05). Urinary excretion of potassium did not differ between groups (Table 1).

NaHS and STS treatment attenuated Ang II-induced hypertension

Ang II infusion increased both systolic (211 ± 9 mmHg vs. 143 ± 2 mmHg, p<0.001) and diastolic (127 ± 10 mmHg vs. 84 ± 2 mmHg, p<0.01) blood pressure compared to controls. Simultaneous treatment with either NaHS or STS decreased systolic blood pressure (SBP) by 22% (164 ± 3 mmHg, p<0.001) and 18% (173 ± 7 mmHg, p<0.001), and diastolic blood pressure (DBP) by 26% (93 ± 8 mmHg, p<0.05) and 30% (89 ± 7 mmHg, p<0.01), respectively (Figure 1A and B). Infusion with Ang II reduced mRNA levels of renin in all groups compared to control (NaCl and NaHS: p<0.05; STS: p<0.01) (Figure 1C).
Table 1. Weight and biochemical parameters at baseline and the end of the study

<table>
<thead>
<tr>
<th>Minipump treatment</th>
<th>NaCl</th>
<th>NaCl</th>
<th>NaHS</th>
<th>STS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daily injection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Body weight (gram) baseline</td>
<td>266 ± 7</td>
<td>261 ± 4</td>
<td>269 ± 4</td>
<td>262 ± 5</td>
</tr>
<tr>
<td>week 3</td>
<td>304 ± 20</td>
<td>211 ± 5 ###</td>
<td>266 ± 16 *</td>
<td>257 ± 16</td>
</tr>
<tr>
<td>Plasma sodium (mmol/L)</td>
<td>145 ± 0.9</td>
<td>139 ± 0.9 ###</td>
<td>142 ± 1.0</td>
<td>142 ± 0.8</td>
</tr>
<tr>
<td>Plasma potassium (mmol/L)</td>
<td>4.1 ± 0.2</td>
<td>3.8 ± 0.2</td>
<td>3.7 ± 0.4</td>
<td>3.7 ± 0.3</td>
</tr>
<tr>
<td>Plasma calcium (mmol/L)</td>
<td>2.1 ± 0.1</td>
<td>2.2 ± 0.1</td>
<td>2.2 ± 0.1</td>
<td>2.3 ± 0.1</td>
</tr>
<tr>
<td>Urinary sodium (mmol/24 h)</td>
<td>2.2 ± 0.7</td>
<td>2.6 ± 0.3</td>
<td>1.7 ± 0.4</td>
<td>4.9 ± 0.5 **</td>
</tr>
<tr>
<td>Urinary potassium (mmol/24 h)</td>
<td>1.8 ± 0.3</td>
<td>1.9 ± 0.1</td>
<td>1.7 ± 0.2</td>
<td>2.0 ± 0.3</td>
</tr>
<tr>
<td>Urinary calcium (mmol/24 h)</td>
<td>0.01 ± 0.01</td>
<td>0.08 ± 0.01 #</td>
<td>0.05 ± 0.02</td>
<td>0.10 ± 0.02</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SEM. #p<0.05, ##p<0.001 vs. control; *p<0.05, **p<0.01 vs. Ang II + NaCl.

Figure 1. Treatment with NaHS and STS attenuated Ang II-induced hypertension and Ang II infusion caused downregulation of renin mRNA expression

Infusion with Ang II increased (A) systolic blood pressure by 48% and (B) diastolic blood pressure by 51%. Treatment with NaHS and STS significantly attenuated the Ang II-induced hypertension. (C) Infusion with Ang II caused downregulation of renin mRNA levels in all groups. (#p < 0.05, ##p < 0.01, ###p < 0.001 vs. control, *p < 0.05, **p < 0.01, *** p < 0.001 vs. Ang II + NaCl)
Improved renal function and reduced proteinuria in NaHS and STS treated rats

Renal function - reflected by creatinine clearance and plasma urea - and proteinuria were similar in all groups at baseline (data not shown). After three weeks of Ang II infusion, vehicle treated rats had an impaired renal function as reflected by a 67% reduction in creatinine clearance (1.4 ± 0.1 mL/min vs. 4.2 ± 0.2, p<0.001) and a 2.9-fold increase in plasma urea (19.0 ± 1.0 mmol/L vs. 6.5 ± 0.2 mmol/L, p<0.001) compared to control rats (Figure 2A and B). Furthermore, proteinuria was significantly increased from week 2 onwards (346 ± 35 mg/24 h vs. 28 ± 11 mg/24 h, p<0.001) (Figure 2C). After three weeks of treatment with NaHS or STS, renal function loss was partially prevented as evidenced by a higher creatinine clearance (NaHS: 2.5 ± 0.3 mL/min, p<0.05; STS: 2.9 ± 0.5 mL/min, p<0.001) and lower plasma urea levels (NaHS: 14 ± 2 mmol/L, p<0.01; STS: 14 ± 2 mmol/L, p<0.01) compared to vehicle treated rats (Figure 2A and B). From week 2 onwards, the 24-hour urinary protein excretion was significantly moderated by NaHS and STS treatment (NaHS: 179 ± 75 mg/24 h, p<0.001; STS: 197 ± 58 mg/24 h, p<0.01) (Figure 2C).

STS increased the excretion of urinary TS

From week 1 onwards, the excretion of urinary TS (p<0.001) was significantly increased in Ang II-infused rats treated with STS. No differences were observed in the other groups (Figure 3).

Effect of NaHS and STS treatment on tubular and glomerular damage

After 3 weeks, kidney injury molecule-1 (KIM-1) mRNA and protein expression were increased in Ang II-infused rats treated with vehicle compared to controls (p<0.001). Both NaHS and STS treated rats showed less tubular damage as evidenced by a 2-fold reduction in proximal tubular damage at mRNA and protein level compared to vehicle treated animals (p<0.05) (Figure 4A, B and C). Also, the glomerular damage marker desmin was increased after three weeks of Ang II infusion (p<0.001). Treatment with NaHS, but not STS, decreased the glomerular protein levels of desmin by 40% (p<0.01) (Figure 5A and B).
Sulfide attenuates Ang II-induced renal damage

Figure 2. Reduction of renal function loss and proteinuria in NaHS and STS treated rats

Three weeks of Ang II infusion decreased renal function as evidenced by a 67% decrease in (A) creatinine clearance and a 2.9-fold increase in (B) plasma urea. Furthermore, (C) proteinuria was significantly increased from week 2 onwards. Treatment with NaHS and STS reduced renal function loss by preserving the creatinine clearance and plasma urea levels. In addition, the development of proteinuria was diminished in NaHS and STS treated rats from week 2 onwards. (###p<0.001 vs. control, *p<0.05, **p<0.01, ***p<0.001 vs. Ang II + NaCl)

Figure 3. Elevated urinary TS excretion in STS treated animals

In rats treated with STS, the excretion of urinary TS was increased from week 1 onwards. In all other groups no differences in urinary TS levels were observed. (***p<0.001 vs. Ang II + NaCl)
Figure 4. Effect of NaHS and STS treatment on tubular damage

(A) KIM-1 mRNA and (B) KIM-1 protein levels were increased by Ang II infusion. Rats treated with NaHS and STS had less tubular damage as evidenced by reduced KIM-1 protein and mRNA levels. (C) Representative photomicrographs of KIM-1 stained renal sections. (###p<0.001 vs. control, *p<0.05 vs. Ang II + NaCl)

Influx of macrophages is reduced by treatment with STS

Ang II infusion increased the number of ED1 positive cells in the renal interstitium more than 2-fold compared to NaCl infused controls (204 ± 46 vs. 86 ± 12, p<0.05). STS and NaHS decreased the number of interstitial macrophages to near control levels (STS: 73 ± 21, p<0.01; NaHS 114 ± 18, p=0.06) (Figure 6A and B).
Figure 5. Effect of NaHS and STS treatment on glomerular damage

(A) Desmin protein levels were increased in glomeruli of Ang II-infused animals treated with vehicle. Treatment with NaHS reduced glomerular desmin levels by 40%. Treatment with STS only showed a trend towards decreased desmin levels. (B) Representative photomicrographs of desmin stained renal sections. (###p<0.001 vs. control, **p<0.01 vs. Ang II + NaCl)

Figure 6. Interstitial inflammation is reduced by treatment with STS

(A) The influx of macrophages was increased 2-fold in Ang II-infused rats treated with vehicle. Treatment with STS, but not NaHS, reduced the number of interstitial macrophages 3-fold. (B) Representative photomicrographs of ED-1 stained renal sections. (#p<0.05 vs. control, **p<0.01 vs. Ang II + NaCl)
Treatment with NaHS and STS reduced oxidative stress

Expression of NOX2 mRNA was increased 1.6-fold after Ang II infusion (p<0.05) (Figure 7A). Furthermore, the urinary excretion of malondialdehyde (MDA) was increased more than 2-fold in Ang II rats treated with vehicle (p<0.001) (Figure 7B). Simultaneous treatment with either NaHS or STS decreased NOX2 mRNA expression by 38% (p<0.01) and 39% (p<0.01), and urinary MDA levels by 35% (p<0.05) and 30% (p<0.05), respectively (Figure 7A and B).

Protective effects of NaHS and STS treatment against renal interstitial changes

TGF-β, a growth factor with proliferative and fibrotic effects on myofibroblasts, is significantly upregulated during Ang II infusion (p<0.05). In rats treated with NaHS and STS, levels of TGF-β mRNA return to near control values (p<0.01) (Figure 8A). Ang II infusion significantly increased mRNA (p<0.05) and protein (p<0.001) expression of the pre-fibrotic marker α-smooth muscle actin (αSMA), indicating ongoing interstitial myofibroblast transformation. STS, but not NaHS, decreased the mRNA and protein expression of αSMA by 50% (p<0.05) (Figure 8B, C and D). The pre-fibrotic effects of Ang II were accompanied by increased fibrotic damage, as evidenced by a significantly higher expression of Collagen 3 mRNA and protein (p<0.05).

Figure 7. Treatment with NaHS and STS reduced oxidative stress

After three weeks of Ang II infusion, (A) NOX2 mRNA and (B) urinary MDA levels were increased 1.6-fold and 2-fold, respectively. Treatment with NaHS and STS reduced NOX2 mRNA expression by 38% and 39% and urinary MDA levels by 35% and 30%, respectively. (#p<0.05, ###p<0.001 vs. control, *p<0.05, **p<0.01 vs. Ang II + NaCl)
Treatment with NaHS and STS reduced the development of fibrosis, resulting in a reduction of Collagen 3 mRNA (p<0.05) and protein (NaHS: p<0.05; STS: p<0.001) to near control levels (Figure 8E, F and G).

Restoration of CSE, CBS and 3-MST mRNA expression with NaHS and STS treatment

Renal mRNA expression of CSE, CBS and 3-MST was significantly decreased after 3 weeks of Ang II infusion (p<0.01). Expression levels were partially restored in Ang II-infused rats that received NaHS and STS (p<0.05) (Figure 9A, B and C).

Vasodilatory effects of NaHS in the isolated perfused kidney setup

Administration of 1 and 5 mM NaHS lowered intrarenal pressure by 44% (p<0.001) and 39% (p<0.05) compared to baseline pressure during phenylephrine (PE) constriction. Lower concentrations of NaHS had no effect on intrarenal pressure. To investigate the role of \( K_{\text{ATP}} \) channels in NaHS-induced vasodilation kidneys were perfused with Glibenclamide, which diminished the vasodilatory potency of 1 mM NaHS (p<0.05). STS showed no effect on intrarenal pressure (Figure 10).
Figure 8. Effect of NaHS and STS on renal fibrosis

(A) In rats infused with Ang II and treated with vehicle, renal TGF-β mRNA levels were upregulated. Treatment with NaHS and STS prevented the upregulation of TGF-β. Ang II infusion caused upregulation of (B) αSMA mRNA and (C) αSMA protein expression. STS, but not NaHS, decreased the levels of αSMA protein and mRNA. (D) Representative photomicrographs of αSMA stained renal sections. (E) Collagen 3 mRNA and (F) Collagen 3 protein levels were increased in Ang II-infused rats treated with vehicle. In NaHS and STS treated rats the formation of Collagen 3 was decreased. (G) Representative photomicrographs of Collagen 3 stained renal sections. (#p<0.05, ###p<0.001 vs. control, *p<0.05, **p<0.01, ***p<0.001 vs. Ang II + NaCl)
Sulfide attenuates Ang II-induced renal damage

Figure 9. Treatment with NaHS and STS restored the expression of CSE, CBS and 3-MST mRNA
After three weeks of Ang II infusion, renal mRNA levels of (A) CSE, (B) CBS and (C) 3-MST are decreased. Treatment with NaHS and STS partially prevented this down regulation. (#p<0.01, ###p<0.001 vs. control, *p<0.05 vs. Ang II + NaCl)

Figure 10. NaHS lowered intrarenal pressure partly via activation of K_{ATP}-channels
In an IPK setup a stable pre-constriction pressure of 200-250 mmHg was induced by perfusion with 1-2 µM PE. Administration of 1 and 5 mM NaHS lowered intrarenal pressure. Simultaneous perfusion with 1 mM Glibenclamide reduced the vasodilatory properties of 1 mM NaHS significantly. Concentrations of NaHS below 1 mM and all concentrations of STS had no effect on intrarenal pressure. (#p<0.05, ###p<0.001 vs. baseline pressure, *p<0.05 vs. NaHS)
Discussion

Exogenous treatment with sulfide donors reduces hypertension, proteinuria, renal damage and renal function loss associated with Ang II infusion. Furthermore, we are the first to show that STS, a clinically applicable compound, has promising renoprotective properties. These data suggest that intervention in sulfur pathways has protective potential in hypertension and hypertensive renal disease.

The effects of exogenous H$_2$S on blood pressure reduction are in line with previous literature showing its preventive and therapeutic properties in experimental hypertension. Endogenous H$_2$S shortage is suggested to be involved in the pathogenesis of hypertension. One of the underlying mechanisms in blood pressure reduction by H$_2$S is its direct effect on vascular smooth muscle cells by sulfhydration and subsequent activation of K$_{ATP}$-channels. The effects of H$_2$S on proteinuria are described less clearly and not in a rectilinear fashion. The antiproteinuric effects of H$_2$S in our model, as structurally evidenced by preservation of podocytes, can be partially explained by the reduction of systemic and intrarenal pressures. Mechanistic evidence for this comes from our ex vivo isolated perfused kidney (IPK) experiments in which we observed a reduction in intrarenal pressure by NaHS. Blockage of the K$_{ATP}$-channels partly decreased the vasodilatory potency of NaHS, suggesting that other mechanisms are involved as well. One of these might be crosstalk between H$_2$S and NO, since the vasorelaxant effects of H$_2$S are partly NO-dependent. Inhibition of NO using L-NG-nitroargininemethyl ester (L-NAME) decreased the potency of H$_2$S in aortic rings. The in vivo effects of STS were unmistakable, but could not be related to direct changes in intrarenal pressure in our IPK setup. Since it is known that TS can be converted to H$_2$S in vivo, we suggest that the IPK setup lacks the proper physiological conditions necessary for this conversion.

H$_2$S directly affects the RAAS, as shown by its capacity to inhibit renin activity and ACE activity. Since we infused Ang II, the contribution of this mechanism is probably low or undetectable because of the existing negative feedback loop between Ang II and renin. Indeed we found low mRNA levels of renin in all the Ang II treated groups. Furthermore, H$_2$S can decrease Ang II-induced activation of mitogen-activated protein kinases and the binding affinity of the Angiotensin-1 (AT-1) receptor in a dose-dependent manner.

Although it is plausible that blood pressure regulation is the primary mechanism of action of H$_2$S in our model, it is known that renal injury in Ang II-induced hypertension can be independent of an elevated blood pressure. This suggests additional protective modes of action of H$_2$S. Since we did not include a group receiving conventional antihypertensive drugs during Ang II infusion, we can not determine whether the protective effects of H$_2$S are solely mediated by blood pressure reduction.

Inflammation is one of the major consequences of renal exposure to hypertension and proteinuria. STS completely prevented Ang II-induced influx of
interstitial macrophages, whereas NaHS only showed a trend. \( \text{H}_2\text{S} \) is widely known for its anti-inflammatory properties and its role in modulation of leukocyte influx.\(^{19,40-44} \) Since proteinuria causes tubular damage and subsequent production of chemokines and attraction of macrophages,\(^{45} \) the anti-inflammatory effects of \( \text{H}_2\text{S} \) can also be explained by a reduction in proteinuria and a subsequent decline in tubular damage, as evidenced by decreased KIM-1 mRNA and protein levels.

Treatment with \( \text{H}_2\text{S} \) influences renal fibrotic pathways as evidenced by a reduction in collagen 3 mRNA and protein, and a downregulation of TGF\( \beta \) mRNA in both treatment groups. The attenuation of fibrosis by \( \text{H}_2\text{S} \) treatment is in concordance with literature showing decreased fibrosis in various organs following \( \text{H}_2\text{S} \) exposure.\(^{42,46-48} \) STS outperformed NaHS with regard to decreased \( \alpha\text{SMA} \) levels, which might be related to the lower level of interstitial macrophages in the former. Other studies showed an inhibiting effect of \( \text{H}_2\text{S} \) on \( \alpha\text{SMA} \) formation.\(^{49,50} \)

Another functional property of \( \text{H}_2\text{S} \) relates to the inhibition of ROS production. Ang II induces oxidative stress by activating NADPH oxidases via the AT-1 receptor.\(^{51} \) We found diminished ROS production in \( \text{H}_2\text{S} \) treated animals as evidenced by lower urinary MDA levels. This might be related to the prevented upregulation of NOX2 in both \( \text{H}_2\text{S} \) treated groups, which is in line with literature showing the effect of \( \text{H}_2\text{S} \) on NADPH oxidases.\(^{52} \) \( \text{H}_2\text{S} \) can also directly scavenge ROS, increase the intracellular glutathione levels, and reduce the amount of ROS produced through modulation of mitochondrial ROS production.\(^{14,23,24} \) Loss of endogenous \( \text{H}_2\text{S} \)-production causes increased susceptibility to renal ischemia.\(^{14} \) Production of ROS plays an important role in the development of hypertension\(^{53} \) and treatment with antioxidants reduces blood pressure in experimental models for hypertension.\(^{54,55} \)

Interestingly, we observed a decline in CSE, CBS and 3-MST mRNA levels in the Ang II-infused animals treated with vehicle. Considering the vasorelaxing properties of \( \text{H}_2\text{S} \) we expected a compensatory increase in these enzymes. However, levels of \( \text{H}_2\text{S} \) and/or its producing enzymes were also decreased in other models of disease in which one might expect compensatory upregulation.\(^{14,25,56-58} \) There is a concordance between progression of renal disease and the decline in \( \text{H}_2\text{S} \) producing capacity of renal tissue,\(^{25} \) suggesting that depleted levels of endogenous \( \text{H}_2\text{S} \) production enhance renal damage. We have not measured \( \text{H}_2\text{S} \) since the reliability of the available techniques is controversial. Treatment with NaHS and STS restored the expression of CSE, CBS and 3-MST which is probably related to a reduction in proteinuria and subsequent salvage of tubular cells, which are major producers of these enzymes. These expression data suggest that there is a shortage in renal endogenous \( \text{H}_2\text{S} \) production in hypertensive renal disease, which implies that intervention in the \( \text{H}_2\text{S} \) producing pathway might be valuable to increase renal levels of sulfide.

The observation that STS as a \( \text{H}_2\text{S} \) donor\(^{27-29} \) has similar protective effects as NaHS, provides us with exciting possibilities for the translation into clinical use. While short term treatment with STS is well tolerated, the long term side effects should be
further explored. One of the drawbacks for long term administration to renal patients is the currently available route of delivery. To date, STS is only given intravenously to patients with calciphylaxis because oral forms of the compound with a validated intestinal uptake have not been developed. It is unknown whether the observed effects of STS are solely mediated by conversion to H₂S or by unknown direct effects of STS itself. Animals treated with STS had significantly increased sulfate levels, indicating that conversion to H₂S and sulfite took place before forming sulfate. Effects of STS on blood pressure in humans have not been described extensively; however there are indications that STS exhibits vasodilating effects and antioxidant properties, probably via the conversion to H₂S.

Taken together, our data reveal novel protective modalities of H₂S treatment in experimental renal disease. Therefore, intervention in H₂S related pathways may have therapeutic potential in hypertension and hypertensive renal damage and deserves further exploration for clinical application.

Acknowledgements

The authors would like to express their gratitude towards Sippie Huitema, Marian Bulthuis, Pieter Klok, Petra Ottens, Susanne Veldhuis and Jacco Zwaagstra for their excellent technical support. Furthermore, we would like to thank Beatrix Blanchard for her valuable help in measuring urinary thiosulfate concentrations. This work was supported by Grants (C08-2254, P13-114) from the Dutch Kidney Foundation and COST Action BM1005: ENOG: European Network on Gasotransmitters (www.gasotransmitters.eu).
References


